Exosome‐derived differentiation antagonizing non‐protein coding RNA with risk of hepatitis C virus‐related hepatocellular carcinoma recurrence

Differentiation antagonizing non‐protein coding RNA is associated with various types of neoplasms. Hepatitis C virus‐related hepatocellular carcinoma has a high risk of recurrence. Here we determined the role of differentiation antagonizing non‐protein coding RNA in hepatitis C virus‐related hepatocarcinogenesis and identified potential therapeutic targets and non‐invasive prognostic markers for long‐term outcome of hepatitis C virus‐related hepatocellular carcinoma after surgical resection.

[1]  M. Kumar,et al.  APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation , 2019, Hepatology International.

[2]  I. Haviv,et al.  Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals , 2019, PLoS genetics.

[3]  M. Ren,et al.  DANCR promotes HCC progression and regulates EMT by sponging miR‐27a‐3p via ROCK1/LIMK1/COFILIN1 pathway , 2019, Cell proliferation.

[4]  Chuanxin Wang,et al.  Serum lincRNA-p21 expression in primary liver diseases and liver metastatic diseases. , 2019, Pathology, research and practice.

[5]  O. Yokosuka,et al.  Exosomes and Hepatocellular Carcinoma: From Bench to Bedside , 2019, International journal of molecular sciences.

[6]  A. Singal,et al.  Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapy , 2018, Alimentary pharmacology & therapeutics.

[7]  J. Tu,et al.  LncRNA-DANCR: A valuable cancer related long non-coding RNA for human cancers. , 2018, Pathology, research and practice.

[8]  M. Fawzy,et al.  Oncogenic long noncoding RNA MALAT1 and HCV-related hepatocellular carcinoma. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[9]  Jie Yu,et al.  Exosome-mediated transfer of lncRNA RP11-838N2.4 promotes erlotinib resistance in non-small cell lung cancer , 2018, International journal of oncology.

[10]  Shuwen Han,et al.  lncRNA-HEIH in serum and exosomes as a potential biomarker in the HCV-related hepatocellular carcinoma. , 2017, Cancer biomarkers : section A of Disease markers.

[11]  A. Singal,et al.  Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review , 2017, Journal of clinical and translational hepatology.

[12]  S. Diederichs,et al.  Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. , 2017, Journal of hepatology.

[13]  C. la Vecchia,et al.  Global trends and predictions in hepatocellular carcinoma mortality. , 2017, Journal of hepatology.

[14]  T. Ma,et al.  Effects of hepatitis C virus core protein and nonstructural protein 4B on the Wnt/β-catenin pathway , 2017, BMC Microbiology.

[15]  Chung‐Feng Huang,et al.  Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy. , 2017, Journal of hepatology.

[16]  N. Sakamoto,et al.  The Paradoxical Effects of Different Hepatitis C Viral Loads on Host DNA Damage and Repair Abilities , 2017, PloS one.

[17]  J. Shindoh,et al.  Impact of Viral Etiology on Postoperative De Novo Recurrence After Hepatectomy for Hepatocellular Carcinoma in Cirrhotic Patients , 2017, Journal of Gastrointestinal Surgery.

[18]  Liqun Wu,et al.  DANCR Acts as a Diagnostic Biomarker and Promotes Tumor Growth and Metastasis in Hepatocellular Carcinoma. , 2016, Anticancer research.

[19]  Ming‐Lung Yu,et al.  Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment , 2016, Clinical Cancer Research.

[20]  J. Bruix,et al.  Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. , 2016, Journal of hepatology.

[21]  L. Bolondi,et al.  Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. , 2016, Journal of hepatology.

[22]  S. Pol.  Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. , 2016, Journal of hepatology.

[23]  Y. Liaw,et al.  The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer Network , 2016, Medicine.

[24]  F. Dieli,et al.  CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA , 2015, Molecular Cancer.

[25]  T. Utsunomiya,et al.  A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. , 2015, Annals of surgery.

[26]  M. Yeh,et al.  Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. , 2014, Journal of hepatology.

[27]  Yue Wang,et al.  Hepatitis B virus X protein (HBx)‐related long noncoding RNA (lncRNA) down‐regulated expression by HBx (Dreh) inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin , 2013, Hepatology.

[28]  H. El‐Serag,et al.  Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.

[29]  Y. Liaw,et al.  A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. , 2006, Hepatology.

[30]  A. Harris,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.

[31]  P. Heagerty,et al.  Survival Model Predictive Accuracy and ROC Curves , 2005, Biometrics.